Gujarat Themis Biosyn Limited held its 45th Annual General Meeting on September 30, 2026, at its registered office in Vapi, Gujarat. The meeting concluded with the adoption of audited financial statements for the fiscal year ended March 31, 2026, and the approval of several special business items, including a preferential issue of equity shares.

Ordinary business approvals

Shareholders adopted the audited financial statements for FY26 along with the Board of Directors' and Auditors' reports. Dr. Dinesh S. Patel, who retires by rotation, was re-appointed as a Director. The meeting also considered the declaration of dividend on equity shares for the financial year ended March 31, 2026.

Special business resolutions

The company sought shareholder approval for multiple strategic initiatives under special business. These included ratifying the remuneration of the Cost Auditor for FY27 and approving commission payments to Non-Executive Chairman Dr. Dinesh S. Patel and Non-Executive Director Dr. Sachin D. Patel.

Key operational and financing resolutions included:

• Approval to avail loans and guarantees from Promoters or Promoter Group to finance acquisition or growth opportunities.
• Raising funds through the issuance of equity shares via a preferential issue.
• Amendment to the Articles of Association of the company.

Meeting proceedings

The meeting commenced at 12:30 pm and concluded at 1:05 pm. Dr. Dinesh S. Patel chaired the session, which was attended by all Directors, including the chairpersons of the Audit, Nomination & Remuneration, and Stakeholder’s Relationship Committees. Mr. Amit Maheshwari, representing M/s. GMJ & Co., the Statutory Auditor, was also present.

The Chairman informed members about the e-voting facility and invited queries regarding the financial statements. All questions raised by shareholders were satisfactorily addressed. The Managing Director provided an update on the company's business activities during the session.

Voting results were to be disseminated to stock exchanges and uploaded on the company's website within two working days of the meeting's conclusion.

Gujarat Themis Biosyn has fixed September 23, 2026, as the record date for determining shareholder eligibility for its final dividend for FY26. The Board of Directors approved the date in a filing with stock exchanges on September 18, 2026.

The dividend payout remains subject to approval by members at the company’s 56th Annual General Meeting (AGM). The AGM is scheduled for Wednesday, September 30, 2026.

Regulatory Compliance

The disclosure was made pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Vineet Gawankar, Company Secretary and Compliance Officer, signed the intimation.

Key Dates